KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Bionano Genomics (BNGO) Gross Margin (2017 - 2025)

Bionano Genomics' Gross Margin history spans 7 years, with the latest figure at 45.74% for Q3 2025.

  • For Q3 2025, Gross Margin rose 18482.0% year-over-year to 45.74%; the TTM value through Sep 2025 reached 45.97%, up 4776.0%, while the annual FY2024 figure was 1.23%, 2525.0% down from the prior year.
  • Gross Margin for Q3 2025 was 45.74% at Bionano Genomics, down from 51.64% in the prior quarter.
  • Across five years, Gross Margin topped out at 51.64% in Q2 2025 and bottomed at 139.07% in Q3 2024.
  • The 5-year median for Gross Margin is 27.92% (2023), against an average of 21.1%.
  • The largest annual shift saw Gross Margin plummeted -16858bps in 2024 before it surged 18482bps in 2025.
  • A 5-year view of Gross Margin shows it stood at 3.79% in 2021, then soared by 479bps to 21.97% in 2022, then rose by 3bps to 22.74% in 2023, then surged by 84bps to 41.86% in 2024, then rose by 9bps to 45.74% in 2025.
  • Per Business Quant, the three most recent readings for BNGO's Gross Margin are 45.74% (Q3 2025), 51.64% (Q2 2025), and 45.5% (Q1 2025).